Cargando…

A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors

Detalles Bibliográficos
Autores principales:	Candelaria, Myrna, Gallardo-Rincón, Dolores, Arce, Claudia, Cetina, Lucely, Aguilar-Ponce, Jose Luis, Arrieta, Oscar, Serrano, Alberto, Perez-Plasencia, Carlos, Gonzalez-Fierro, Aurora, de la Cruz-Hernandez, Erik, Revilla-Vazquez, Alma, Chavez-Blanco, Alma, Trejo-Becerril, Catalina, Perez-Cardenas, Enrique, Taja-Chayeb, Lucia, Camargo, Maria F, Robles, Elizabeth, Dueñas-Gonzalez, Alfonso
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1796571/ http://dx.doi.org/10.1186/1471-2407-7-S1-A27

Ejemplares similares

Epigenetic therapy with hydralazine and valproate associated to cisplatin chemoradiation in FIGO stage IIIB. A phase II study
por: Candelaria, Myrna, et al.
Publicado: (2007)

A proof-of-principle study of epigenetic therapy with hydralazine and magnesium valproate plus doxorubicin cyclophosphamide as neoadjuvant therapy for locally advanced breast cancer
por: Arce, Claudia, et al.
Publicado: (2007)

Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study
por: Chavez-Blanco, Alma, et al.
Publicado: (2005)

A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes
por: Zambrano, Pilar, et al.
Publicado: (2005)

Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines
por: Chavez-Blanco, Alma, et al.
Publicado: (2006)

DNA Methylation-Independent Reversion of Gemcitabine Resistance by Hydralazine in Cervical Cancer Cells
por: Candelaria, Myrna, et al.
Publicado: (2012)

Hydralazine target: From blood vessels to the epigenome
por: Arce, Claudia, et al.
Publicado: (2006)

Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine
por: Segura-Pacheco, Blanca, et al.
Publicado: (2006)

Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells
por: Pérez-Cárdenas, Enrique, et al.
Publicado: (2018)

A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer
por: Arce, Claudia, et al.
Publicado: (2006)

Serum nucleosomes during neoadjuvant chemotherapy in patients with cervical cancer. Predictive and prognostic significance
por: Trejo-Becerril, Catalina, et al.
Publicado: (2005)

HER2 expression in cervical cancer as a potential therapeutic target
por: Chavez-Blanco, Alma, et al.
Publicado: (2004)

Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer
por: Taja-Chayeb, Lucia, et al.
Publicado: (2006)

Response to Hydralazine-Valproate in a Patient with Mycosis Fungoides
por: Dueñas-Gonzalez, Alfonso, et al.
Publicado: (2010)

Epigenetics of cervical cancer. An overview and therapeutic perspectives
por: Dueñas-González, Alfonso, et al.
Publicado: (2005)

Radiosensitizers in cervical cancer. Cisplatin and beyond
por: Candelaria, Myrna, et al.
Publicado: (2006)

Identification of a novel germ-line mutation in the TP53 gene in a Mexican family with Li-Fraumeni syndrome
por: Taja-Chayeb, Lucia, et al.
Publicado: (2009)

Polymorphisms of the thiopurine methyl transferase gene in healthy and acute lymphoblastic leukemia mestizos
por: Candelaria, Myrna, et al.
Publicado: (2007)

Concurrent chemoradiation with carboplatin for locally advanced cervical cancer at high-risk for developing cisplatin-induced renal dysfunction
por: Cetina, Lucely, et al.
Publicado: (2007)

Antitumor Effects of Systemic DNAse I and Proteases in an In Vivo Model
por: Trejo-Becerril, Catalina, et al.
Publicado: (2016)

Cancer Progression Mediated by Horizontal Gene Transfer in an In Vivo Model
por: Trejo-Becerril, Catalina, et al.
Publicado: (2012)

Radiation-sparing managements for cervical cancer: a developing countries perspective
por: Candelaria, Myrna, et al.
Publicado: (2006)

Chemoradiation with cisplatin followed by either brachytherapy or radical hysterectomy. A non-randomized comparison in FIGO stages IB2-IIA
por: Cetina, Lucely, et al.
Publicado: (2007)

Brachytherapy versus radical hysterectomy after external beam chemoradiation: a non-randomized matched comparison in IB2-IIB cervical cancer patients
por: Cetina, Lucely, et al.
Publicado: (2009)

The health system and access to treatment in patients with cervical cancer in Mexico
por: Arango-Bravo, Eder A., et al.
Publicado: (2022)

Routine management of locally advanced cervical cancer with concurrent radiation and cisplatin. Five-year results
por: Cetina, Lucely, et al.
Publicado: (2006)

Pre-exenterative chemotherapy, a novel therapeutic approach for patients with persistent or recurrent cervical cancer
por: Lopez-Graniel, Carlos, et al.
Publicado: (2005)

Molecular characterization of BRCA1 and BRCA2 genes in breast cancer patients under 40 years-old or with familiar cancer history
por: Millan, Silvia Vidal, et al.
Publicado: (2007)

New molecular targets against cervical cancer
por: Duenas-Gonzalez, Alfonso, et al.
Publicado: (2014)

ctDNA Is Useful to Detect Mutations at Codon 641 of Exon 16 of EZH2, a Biomarker for Relapse in Patients with Diffuse Large B-Cell Lymphoma
por: Díaz-Chávez, José, et al.
Publicado: (2022)

A combination of inhibitors of glycolysis, glutaminolysis and de novo fatty acid synthesis decrease the expression of chemokines in human colon cancer cells
por: Schcolnik-Cabrera, Alejandro, et al.
Publicado: (2020)

Prognostic significance of pathological response after neoadjuvant chemotherapy or chemoradiation for locally advanced cervical carcinoma
por: Candelaria, Myrna, et al.
Publicado: (2006)

Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
por: Candelaria, Myrna, et al.
Publicado: (2021)

Impact of metabolic syndrome on the risk of endometrial cancer and the role of lifestyle in prevention
por: Pérez-Martín, Alejandra Rocío, et al.
Publicado: (2022)

Does Therapeutic Repurposing in Cancer Meet the Expectations of Having Drugs at a Lower Price?
por: Gonzalez-Fierro, Aurora, et al.
Publicado: (2023)

The prince and the pauper. A tale of anticancer targeted agents
por: Dueñas-González, Alfonso, et al.
Publicado: (2008)

Hydralazine-Induced Vasculitis
por: Gandhi, Pulkit, et al.
Publicado: (2023)

Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy?
por: Perez-Plasencia, Carlos, et al.
Publicado: (2006)

Hydralazine-associated adverse events: a report of two cases of hydralazine-induced ANCA vasculitis
por: Zuckerman, Roman, et al.
Publicado: (2018)

Hydralazine-Induced Vasculitis With Gastrointestinal Pseudomelanosis
por: Novikov, Aleksey, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_o1ikoju1rgot5n8lcoiqllf0if